NEXI

Neximmune Inc

NEXI | $3.22 -2.42% -2.48% 23K

(0.0% 1d) (-44.9% 1m) (723.7% 1y) (0.0% 2d) (0.0% 3d) (-11.3% 7d) (262.77% volume)
Earnings Calendar: 2022-11-11
Market Cap: $ 4,414,784
https://www.neximmune.com
Sec Filling | Patents | 44 employees

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology.

ceiling immunotherapy t-cell

add to watch list Paper trade email alert is off

Press-releases

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2024-02-06 (Crawled : 22:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| -70.03% | O: -0.48% H: 5.16% C: -12.05%
nasdaq million direct offering

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2024-02-02 (Crawled : 19:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| Email alert Add to watchlist
nasdaq million direct offering

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
Published: 2023-10-24 (Crawled : 12:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| -22.6% | O: 5.9% H: 0.0% C: -4.49%
partnership research diabetes

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| -29.61% | O: -6.59% H: 4.64% C: -14.35%
immunotherapy meeting

NexImmune Announces 1-for-25 Reverse Stock Split
Published: 2023-10-18 (Crawled : 15:30) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| -42.99% | O: 4.07% H: 3.91% C: -22.17%

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
Published: 2023-08-31 (Crawled : 21:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| -42.33% | O: -3.89% H: 9.52% C: 0.0%
platform

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| 800.0% | O: 8.06% H: 0.48% C: -9.04%
nexi-001 positive aml meeting trial

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
Published: 2023-05-22 (Crawled : 20:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| 564.56% | O: -6.96% H: 1.81% C: -18.59%
presentation meeting

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-05-15 (Crawled : 20:00) - globenewswire.com
NEXI | $3.22 -2.42% -2.48% 23K

| 1024.6% | O: 5.93% H: 4.48% C: -3.91%
business financial results

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
Published: 2023-04-26 (Crawled : 22:00) - biospace.com/
NEXI | $3.22 -2.42% -2.48% 23K

| 695.45% | O: 0.2% H: 0.55% C: -6.58%
presentation meeting

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-23-056514	4	2023-11-22	2023-11-22	Sell	S	3992	0
0001209191-23-056514	4	2023-11-22	2023-11-21	Sell	S	3833	3992